CS
PRDS

Credit Suisse’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Credit Suisse’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$2 – 3874
2022
Q4 		$2 Sell
1
-188
-99% -$238 ﹤0.01% 3908
2022
Q3 		$0 Buy
189
+175
+1,250% +$522 ﹤0.01% 4436
2022
Q2 		$0 Buy
+14
New +$85 ﹤0.01% 4500

Other funds holding PRDS

FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Credit Suisse's PRDS Position: Q1 2023 in Review

Credit Suisse sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q1 2023, closing a stake of 1 share — an estimated $2 sold.

Credit Suisse first reported a position in PRDS in Q2 2022 and held it in 3 quarters. The position peaked at $2 in Q4 2022. 61 funds tracked by Wall St. Rank hold PRDS as of Q1 2023.

  • Credit Suisse reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 1 Pardes Biosciences, Inc. Common Stock share in Q1 2023, an estimated $2.
  • Credit Suisse first reported a position in Pardes Biosciences, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Credit Suisse's Pardes Biosciences, Inc. Common Stock position peaked at $2 in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.